ALTEOGEN Inc. is a leading bio company whose portfolio includes next-generation biobetters, biosimilars, and proprietary biologics. They are focusing on three cutting-edge areas of the industry – long-acting biobetters, proprietary antibody-drug conjugate (ADC), and antibody biosimilars with high complexity.
Latest News
- The top 1% of stock investment returns net purchased Alteogen, Korea Electric Power Corp., and Kakao.. - 매일경제
- Alteogen Healthcare wins domestic distribution rights for LG Chem's anti-adhesion agent - KBR
- 1. As Alteogen, the No. 1 KOSDAQ company by market capitalization, has been embroiled in a patent di.. - 매일경제
- Alteogen’s trading volume surges, exceeding Samsung for the day - 조선일보
- It has been confirmed that Merck (MSD), a large global pharmaceutical company, has filed a patent in.. - 매일경제
- Alteogen reshapes S. Korea’s biotech landscape with market success - MSN
- While pharmaceutical-related stocks have fallen all at once in the U.S. stock market, the domestic s.. - 매일경제
- Alteogen reshapes S. Korea’s biotech landscape with market success - 조선일보
- Alteogen draws Daiichi in $300M pact for subcutaneous Enhertu - BioWorld Online
- Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu - PMLiVE
- Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology - The Manila Times
- Alteogen CEO expresses confidence in ALT-B4’s competitiveness - pulse.mk.co.kr
- "K Bio" has been at the forefront of Korea's exports by delivering good news of technology exports e.. - 매일경제
- When you introduce Alteogen, people are surprised three times. I'm surprised to hear that a company.. - 매일경제
- Alteogen jumps as it inks licence deal with Daiichi Sankyo - The Pharma Letter
